NCT06408753View on ClinicalTrials.gov

Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

November 30, 2023

Study Completion Date

March 27, 2024

Conditions
Hepatocellular Carcinoma Non-resectableStereotactic Body Radiotherapy
Interventions
PROCEDURE

sterotatic body radiotherapy

checkpoint inhibitors with or without sterotatic body radiotherapy

Trial Locations (1)

Unknown

Department of Clinical Oncology, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT06408753 - Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT | Biotech Hunter | Biotech Hunter